血清乳酸脱氢酶血管内皮生长因子对TACE近期疗效的评估价值  

Value of serum lactate dehydrogenase and vascular endothelial growth factor in evaluating short-term efficacy of TACE

作　　者：乔彬彬[1] 施昌盛[1] 虞希祥[1] 王舒婷[1] 肖池金[1] 

机构地区：[1]温州医科大学附属第三医院介入科,浙江省温州市325200

出　　处：《中国肿瘤临床》2014年第15期964-967,共4页Chinese Journal of Clinical Oncology

摘　　要：目的:探讨原发性肝癌(PLC)患者血清乳酸脱氢酶(LDH)与血管内皮生长因子(VEGF)对肝动脉化疗栓塞术(TACE)近期疗效的评估价值。方法:检测70例肝癌患者TACE术前第1天、术后第3天、第7天、第14天及第21天的血清LDH及VEGF表达水平。根据mRECIST标准进行术后疗效评估,将完全缓解+部分缓解+疾病稳定的病例归为获益组(n=46),疾病进展者归为无效组(n=24)。结果:LDH及VEGF在术后第14天及21天,无效组的表达水平均高于获益组(P<0.05),LDH及VEGF在术后第21天的百分比变化无效组高于获益组(P<0.05)。LDH及VEGF的术后21天百分比变化在ROC曲线中的曲线下面积分别为65.9%和85.5%;ROC曲线中LDH及VEGF百分比变化的最佳切点对应的约登指数分别为0.272和0.745。结论:LDH及VEGF的表达水平均可用于TACE的近期疗效评估,其表达水平越低或升高越小,TACE的近期疗效越好。To investigate the assessed value of serum lactate dehydrogenase （LDH） and vascular endothelial growth factor （VEGF） for short-term efficacy of transcatheter arterial chemoembolization （TACE）. Methods： Serum concentrations of LDH and VEGF from 70 patients with primary liver cancer on the 1st day before therapy and the 3rd, 7th, 14th, and 21st day after TACE therapy was determined. The benefit group includes complete remission, partial remission, and stable disease, while the invalid group includes only disease progression. Results：The serum levels of LDH and VEGF in the invalid group were significantly higher than those in the benefit group on the 14th and 21st days after TACE （P〈0.05）. The percentage changes of the serum concentrations of LDH and VEGF in the invalid group were higher than those in the benefit group on the 21st day after TACE. Percentage changes on the 21st day after TACE were drawn into the ROC curve;the areas under the curve were 65.9%and 85.5%. The optimal cutoff points of LDH and VEGF, which correspond to the Youden index, were 0.272 and 0.745, respectively. Conclusion：The expression levels of VEGF and LDH can be used to assess the short-term efficacy of TACE. A lower expression level corresponds to short-term efficacy.

关 键 词：原发性肝癌 肝动脉化疗栓塞 乳酸脱氢酶 血管内皮生长因子 疗效 

分 类 号：R735.7[医药卫生—肿瘤]